
Surgical Science Q1 2023 - Outperformers tend to keep outperforming

Redeye updates its estimates following Surgical Science's Q1 2023 report, which took our forecasts to the woodshed. Educational Products sales came in c35% above our estimate. The company posted strong EBITDA and EBIT margins; both c2%-points higher than we anticipated. We believe that growth will moderate in the future while margin expansion continues. We raise our estimates and valuation.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Surgical Science Q1 2023 - Outperformers tend to keep outperforming